Accessibility
Page map
Search
Contrast
Font size A- A A+

Completed projects

Research projects carried out at the Institute of Medical Biology of the Polish Academy of Sciences

  1. POIG.01.03.02-00-043/10; Coverage of patent proceedings costs for a patent application entitled “Tools and methods useful in characterising the immunooxic activity of xenobiotic substances”; prof. dr hab. Jarosław Dastych
  2. POIG.01.01.02-10-107/09; Research on molecular mechanisms at the interface of the human organism – pathogen – environmental factors (InterMolMed), ; prof. dr hab. Jarosław Dziadek
  3. 261861; EU-OPENSCREEN European Infrastructure of Open Screening Platforms for Chemical Biology INFRA-2010-2.2.6 POL-OPENSCREEN; prof. dr hab. Zbigniew Leśnikowski
  4. PBZ-MNiSW-07/I/2007; Bio‑phosphates as well as nucleotides and their congeners as diagnostics and next‑generation drugs. Subproject: Screening laboratory – virology, bacteriology; prof. dr hab. Zbigniew Leśnikowski
  5. PBZ-MNiSW-07/I/2007; Bio‑phosphates as well as nucleotides and their congeners as diagnostics and next‑generation drugs. Subproject: Nucleoside phosphates and their oligomers modified with a lyophilic carboranyl pharmacophore; prof. dr hab. Zbigniew Leśnikowski
  6. PL0107; Cell‑based biosensors for automated environmental pollution monitoring; dr hab. Jarosław Dastych
  7. INCA/149/2008; Cooperation of integrins with metalloproteinases during the growth of colorectal cancer cells. Proteoglycans and their fragments produced by metalloproteinases, their role in stem cell differentiation – significance for tumor and angiogenesis; prof. dr hab. Czesław Cierniewski
  8. PL0270; Prenatal and perinatal infections with human cytomegalovirus; dr Edyta Paradowska
  9. POMOST_C/16; Funding agreement under POMOST programme (support for pregnant women); dr Patrycja Przygodzka
  10. POMOST_C/24; Funding agreement under POMOST programme (support for pregnant women); mgr Małgorzata Ziółkiewicz
  11. 202952; Molecular Mechanisms of Tissue Fibrosis; Task 2 Coordinator dr hab. Joanna Boncela
  12. 198; How mycobacteria sense and respond to environment al chan ges: the role of orphan histidine kinases?; dr Renata Płocińska
  13. 2 P06D 025 29; Melatoninergic system in the turkey retina and pineal gland – new aspects of regulation of hormone synthesis and melatonin receptor activity; prof. dr hab. Jolanta Zawilska
  14. 2 P05E 092 30; Studies on the importance of ficolin L deficiency and other lectin pathway complement activation factors in children with allergic respiratory diseases and recurrent respiratory tract infections; dr hab. Maciej Cedzyński
  15. 2 P04A 034 30; Action of interleukin‑4 on the expression and activity of DNA‑dependent protein kinase in eukaryotic cells; dr hab. Jarosław Dastych
  16. 1 T09A 121 30; Metallacarboranes – a new type of electrochemical markers for construction of DNA biosensors; dr Agnieszka Olejniczak
  17. N302 035 31/3172; Enzymes of mycolic acid biosynthesis in Mycobacterium tuberculosis as targets for new antitubercular drugs; dr Anna Brzostek
  18. N405 051 32/3592; Adenosine derivatives modified with boron clusters – a new type of modulators of biological functions of human neutrophils in vitro; prof. dr hab. Zbigniew Leśnikowski
  19. N N303 3582 33; DNA repair processes in the pathogenesis of tuberculosis mycobacteria; dr hab. Jarosław Dziadek
  20. N N401 1224 33; Polymorphism of selected human cytomegalovirus (HCMV) genes in strains isolated from immunocompromised patients; prof. dr hab. Zbigniew Leśnikowski
  21. N N405 3480 33; New derivative of “Vitravene” – an anti‑HCMV drug, modified with boron clusters as a lyophilic pharmacophore; prof. dr hab. Zbigniew Leśnikowski
  22. N N301 3386 33; Novel intrinsic role of plasminogen activator inhibitors in endothelial cells; dr Joanna Boncela
  23. N N407 356834; Involvement of adhesion and Toll‑like receptors in interactions of peripheral blood neutrophils with ovarian cancer cells in vitro; dr hab. Zofia Sułowska
  24. N N301 164335; Importance of epigenetic regulation of HIF‑1α gene expression in blood cells; dr Aurelia Walczak-Drzewiecka
  25. N N401 021035; Local synthesis, its regulatory mechanisms, and expression changes of selected lectins and serine protease MASP‑2 in ovarian tumors; dr hab. Anna Świerzko
  26. N N401 005035; Biological activity of platelet basic protein (PBP) and its derivatives (beta‑TG, NAP‑2) – role in inflammatory states; dr hab. Maria Anna Kowalska
  27. N N401 162137; Pre‑validation of molecular TRS‑PCR method for genotyping Mycobacterium gordonae and Mycobacterium avium; dr hab. Paweł Parniewski
  28. N N402 353438; Studies of selected innate immune factors in intensive care unit patients; dr hab. Maciej Cedzyński
  29. N N301 507638; Searching for ligands for the nuclear receptor RORγ as potential therapeutic agents in autoimmune diseases; dr Marcin Ratajewski
  30. N N301 425438; Exploring signaling pathways involved in the pro‑apoptotic action of hypocretin (orexin) in rat cortical cells; prof. dr hab. Jolanta B. Zawilska
  31. N N302 113138; Recombinant thymosin β4 biotechnology – standardization of production and biological activity; dr Radosław Bednarek
  32. N N204 531739; Boron clusters as electrochemical markers for construction of DNA biosensor for viral infection detection; dr hab. Agnieszka Olejniczak
  33. N N407095840; Nitric oxide donors as agents supporting anticancer effects of compounds used in ovarian therapy; dr hab. Magdalena Klink
  34. 2011/01/B/NZ3/00194; PAI‑1 as a regulator of the balance between survival and death in endothelial cells; dr Joanna Boncela
  35. 2011/01/M/NZ6/01764; Role of interleukin‑8 in tuberculosis pathogenesis; prof. dr hab. Jarosław Dziadek
  36. 2011/01/N/NZ6/04186; Identification of a novel DNA replication initiation mechanism in Mycobacterium smegmatis; mgr Alina Minias
  37. IP2011 042571; Signal transduction proteins MtrA and MtrB and their role in cell division regulation in tuberculosis mycobacteria; dr Renata Płocińska
  38. IP2011 045171; Searching for new determinants of expression of the human ABCB8 gene, associated with multidrug resistance in melanoma; dr Marcin Ratajewski
  39. 2011/02/A/NZ3/00068; Early molecular mechanisms in invasive colorectal cancer cells induced by genes controlled by Snail transcription factor; prof. dr hab. Maria Anna Kowalska
  40. 2011/03/B/NZ4/00046; Effect of receptor interaction of L‑ and D‑lactate on cervical cancer cells. Modulation by lactate of DNA damage repair induced by chemotherapeutics; dr Waldemar Wagner
  41. PBS1/A8/5/2012; Microbial activators in denitrifying deposits used for remediation of nitrate pollution under the Water Framework Directive and Nitrates Directive. MIKRAZO; Tasks 3, 4, 5 coordinator: prof. dr hab. Jarosław Dziadek
  42. PBS1/A9/16/2012; Innovative agent against liver cancer (HCC) – HCC‑TOX; Task 3 coordinator: prof. dr hab. Jarosław Dastych
  43. PBS1/B8/6/2012; Development of a field diagnostic test for honey bee infection by the pathogen Nosema ceranae – BEEFREE; Coordinator: prof. dr hab. Jarosław Dastych
  44. 2012/05/N/NZ2/00622; Identification of the mechanism of acetyl‐CoA carboxylation in pathogenic and non‑pathogenic Mycobacterium strains; mgr Jakub Pawełczyk
  45. 2012/07/B/NZ4/01770; Modulation of blood‑brain barrier function by nanoparticles – environmental threats and nanotherapeutics; dr Katarzyna Kania
  46. 2012/07/N/NZ6/02964; Study of the importance of ficolins in anti‑infective immunity in acute myeloid leukemia patients undergoing chemotherapy; mgr Anna Sokołowska
  47. 2013/11/N/NZ6/03097; Mycobacterium species and strains with variable cell wall composition: role of pattern‐recognition receptors in activation of innate immune response; mgr Iwona Karwaciak
  48. 2013/11/D/NZ6/02888; Importance of orphan regulatory proteins involved in two‑component signal transduction in physiology and pathogenesis of Mycobacterium tuberculosis cells; dr Renata Płocińska
  49. 2013/11/B/NZ6/01739; Study of the importance of lectin‑pathway complement activation factors in hematological cancer patients undergoing autologous hematopoietic stem cell transplantation; dr hab. Maciej Cedzyński
  50. 2014/13/B/NZ1/03989; A new type of modulators of purinergic receptors – synthesis and ligand‑receptor interaction studies; prof. dr hab. Zbigniew Leśnikowski
  51. 2014/13/N/NZ5/03665; Mechanism and consequences of Ficolin‑3 interactions with human cancer cells; mgr Mateusz Michalski
  52. 2014/13/B/NZ7/02317; Risk factors of congenital and postnatal cytomegalovirus infections; dr Edyta Paradowska
  53. 2014/15/B/NZ6/01565; Role of Mycobacterium tuberculosis cholesterol oxidase in modulation of TLR2‑dependent signaling pathway in human macrophages and neutrophils; dr hab. Magdalena Klink
  54. 2014/15/B/NZ7/01002; Functionalized carbohydrate pharmacophores as potential antitubercular agents – mechanism of action; prof. dr hab. Jarosław Dziadek
  55. 2015/16/T/NZ6/00412; Study of ficolin H interaction with bacterial lipopolysaccharides and biological effects thereof; mgr Mateusz Michalski
  56. 2014/14/E/ST5/00577; DNA‑binding molecules – synthesis and properties of DNA intercalators containing boron clusters; dr hab. Agnieszka Olejniczak
  57. 2015/16/W/ST5/00413; Oligopodal nucleic acid‑boron cluster composites – new material for bionanotechnology; prof. dr hab. Zbigniew Leśnikowski
  58. 2015/17/B/NZ3/03764; Insights into the response mechanisms of ovarian cancer cells to adenine nucleosides modified with metallacarborane clusters with potential antiproliferative and pro‑apoptotic properties; dr Katarzyna Bednarska
  59. 2015/17/B/NZ5/00142; Role of sirtuin 2 (SIRT2) in drug resistance of melanoma; dr Marcin Ratajewski
  60. 2015/17/B/NZ6/04252; Influence of hypoxia on mast cell capacity to enhance pro‑inflammatory activity of Th17 lymphocytes; prof. dr hab. Jarosław Dastych
  61. 2015/17/N/NZ6/02015; RIG‑I‑like receptors and human cytomegalovirus infections in the placenta: too much of a good thing?; mgr Agnieszka Jabłońska
  62. 2015/18/E/NZ5/00733; Identification of genes and epigenetic processes involved in human Th17 cell differentiation; dr Marcin Ratajewski
  63. 2015/19/B/NZ703856; Antibodies stimulating endocytosis of multidrug resistance transporters as drug carriers; dr hab. Łukasz Pułaski
  64. 2015/17/B/NZ6/04250; Genetic and epigenetically regulated determinants of ficolin‑2 deficiency in susceptibility to infections in preterm newborns; dr hab. Anna Świerzko
  65. 2015/19/B/NZ7/03778; Phosphorylation of the A/B domain as a mechanism determining substrate specificity of two isoforms (RORγ and RORγ”I”) of the RORC nuclear receptor; dr Marcin Ratajewski
  66. 2015/19/B/NZ6/02978; RecA‑independent response of tuberculosis mycobacteria to DNA damage; dr hab. Anna Brzostek
  67. 2015/19/D/NZ1/02842; The involvement of RNA degradosome core proteins in regulation of mycobacteria metabolism; dr Przemysław Płociński
  68. 2015/19/D/NZ6/03011; Vitamin B12 and the “persistence” state in mycobacteria; dr Alina Minias
  69. 2016/22/E/NZ3/00341; Neuromedin U as a novel potential regulator of metastasis in colorectal and rectal cancer; dr Patrycja Przygodzka
  70. 2016/23/B/NZ7/01204; Identification of Mycobacterium tuberculosis ligands binding human serum amyloid A (SAA) and determination of the biological role of Mtb–SAA interactions; prof. dr hab. Jarosław Dziadek
  71. 2016/23/D/NZ1/02611; New strategies in cancer therapy – bioninorganic conjugates of cytostatics and boron clusters; prof. dr hab. Zbigniew Leśnikowski
  72. 2017/25/B/NZ7/01290; RNA metabolism enzymes, PAP I and PNPase, as targets for new antitubercular drugs: functional characterization; prof. dr hab. Jarosław Dziadek
  73. 2017/25/B/NZ7/00124; New 2,4‑dip-substituted pyridine derivatives – synthesis, in vitro antitubercular activity, pharmacophore modeling, molecular targets and mechanisms of action against Mycobacterium tuberculosis strains; prof. dr hab. Jarosław Dziadek
  74. Participation of the POL‑OPENSCREEN consortium in the joint international venture “European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastructure Consortium (EU‑OPENSCREEN ERIC)”; prof. dr hab. Zbigniew Leśnikowski
  75. 2018/02/X/NZ3/00144; Development of an optimal research model for the project “Non‑canonical functions of ABCC4 protein in cancer progression”; dr Jakub Kryczka
  76. 2018/02/X/NZ3/00705; Analysis of potential post‑transcriptional and post‑translational regulation mechanisms of SNAIL1/2 transcription factors and their mutual dependencies in the context of heterogeneity and chemoresistance of ovarian cancer cells in vitro; dr Michał Kiełbik
  77. 2018/02/X/NZ1/01710; Evaluation of the potential use of CRISPR III‑A system as a tool for genome engineering; dr Dawid Grzela
  78. Functional study of protein complexes in mycobacteria for discovery of new antitubercular drugs; dr Przemysław Płociński
  79. 2018/29/B/NZ5/01756; How platelet microparticles affect invasiveness of colorectal cancer cells during metastasis – can we change it?; prof. dr hab. Anna Maria Kowalska
  80. European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (EU-OPENSCREEN ERIC) (EU-OS) prof. dr hab. Zbigniew Leśnikowski
  81. 2018/31/B/NZ6/03514; Host‑pathogen interactions: bacterial outer membrane vesicles as shields for complement-targeting drugs; dr hab. Anna Świerzko
  82. 2019/33/B/NZ7/00795; Application of artificial intelligence based on machine learning to search for new substances modulating RORγ/RORγT activity; dr hab. Marcin Ratajewski
  83. 2019/33/B/NZ7/02872; Studies of molecular mechanisms related to HIV and CMV infections in ovarian cancer pathogenesis; prof. dr hab. Edyta Paradowska
  84. 2019/35/N/NZ7/01618; Molecular mechanisms of RORγ/RORγT interactions with AT7519—analysis of tissue‑specific engagement and Th17 lymphocyte activation; mgr inż. Kaja Karaś
  85. 2019/35/D/NZ5/00558; Evaluation of SNAIL1 and SNAIL2 transcription factor involvement in development of chemoresistance in ovarian cancer cells in the context of invasiveness; dr Michał Kiełbik
  86. 2019/35/B/NZ7/00942; Factors of Mycobacterium tuberculosis influencing tuberculosis transmission frequency; prof. dr hab. Ewa Augustynowicz-Kopeć
  87. 2020/37/N/NZ6/01887; Collectin liver 1 (CL‑L1) and collectin kidney 1 (CL‑K1) in susceptibility of preterm infants to infection; mgr Gabriela Gajek
  88. 2021/05/X/NZ3/01620; Optimization of procedure for obtaining Mycobacterium extracellular vesicles; dr Agnieszka Szala-Poździej
  89. 2022/06/X/NZ3/00551; Assessment of the impact of M1 versus M2 macrophages on expression of proteins associated with proliferation and survival of ovarian cancer cells; dr Izabela Szulc-Kiełbik
  90. 2023/07/X/NZ5/00635; Role of interleukin IL17B receptor (IL17RB) in multidrug resistance in hepatocellular carcinoma; dr Joanna Pastwińska

 

 

›